Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation-Reference-Cited by-同舟云学术

Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation

Published:2021-03-25 Issue:9 Volume:62 Page:2161-2168
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Cazelles Clarisse¹,Belhadj Karim¹,Vellemans Hélène²,Camus Vincent²,Poullot Elsa³,Gaulard Philippe³⁴⁵,Veresezan Liana⁶,Itti Emmanuel⁴⁷,Becker Stéphanie⁸,Carvalho Muriel⁹,Dupuis Jehan¹,Le Bras Fabien¹,Lemonnier François¹⁴⁵,Roulin Louise¹,El Gnaoui Taoufik¹,Jardin Fabrice²,Mounier Nicolas¹⁰,Tilly Hervé²,Haioun Corinne¹⁴⁵

Affiliation:

1. Lymphoid Malignancies Unit, Hôpital Henri Mondor, AP-HP, Créteil, France

2. Department of Hematology and U1245, Rouen, France

3. Department of Pathology, Hôpital Henri Mondor, AP-HP, Créteil, France

4. Paris-East, Créteil University, Créteil, France

5. INSERM U955, Mondor Biomedical Research Institute, Créteil, France

6. Department of Pathology, Rouen, France

7. Department of Nuclear Medicine, Hôpital Henri Mondor, AP-HP, Créteil, France

8. Department of Nuclear Medicine, Rouen, France

9. Department of Pharmacy, Hôpital Henri Mondor, AP-HP, Créteil, France

10. Onco-Hematology Department, Hôpital l’Archet, Nice, France

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1901090

Reference26 articles.

1. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project - NCBI. [cited 2020 Mar 3]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&querykey=1.

2. 2016 US lymphoid malignancy statistics by World Health Organization subtypes

3. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

4. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

5. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas;Blood Advances;2024-09-10

2. SOHO State of the Art Updates and Next Questions | Contemporary Role of Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Era of Cellular Therapies;Clinical Lymphoma Myeloma and Leukemia;2024-08

3. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group;Clinical Cancer Research;2024-06-20

4. Time‐dependent cost comparison and health economic impact analysis of second‐line interventions for transplant‐ineligible patients with relapsed or refractory diffuse large B cell lymphoma;European Journal of Haematology;2024-06-10

5. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting;Clinical Lymphoma Myeloma and Leukemia;2024-05